Trial Profile
An Open label multi- facilities cooperation randomized control trial to verify renoprotective effects of Aliskiren treatment in the chronic kidney disease (CKD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Antihypertensives
- Indications Hypertension
- Focus Pharmacodynamics
- 09 Jan 2012 New trial record